Please login to the form below

Not currently logged in
Email:
Password:

Black triangle monitoring warning to be used across EU

Use of symbol is part of EMA plans to strengthen pharmacovigilance

EMA black triangleAll medicines subject to additional monitoring in Europe will have to carry a black inverted triangle warning in line with new pharmacovigilance rules published by the European Medicines Agency (EMA).

The addition of the symbol - which already used by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) – is part of EMA plans to strengthen drug safety measures across the EU in the wake of such controversies as the continued marketing of Servier's Mediator despite safety concerns.

Medicines that will need to carry the symbol by September 2013 include all drugs that contain a new active substance and all biological medicines authorised by the EMA after January 1, 2011.

All treatments that require additional data after authorisation and medicines subject to restrictions will also need to carry the black triangle by this date.

A full list of affected medicines will be published within the next few months.

The symbol will need to appear on both the summary of product characteristics and package leaflet, and will be accompanied by a statement explaining that the medicine is under additional monitoring, as well as a further explanatory sentence.

In addition, updated product information will encourage patients and healthcare professionals to report adverse reactions, with new label requirements to identify the different ways to report an adverse event, including electronic reporting and the appropriate postal address.

According to the EMA, these changes will “allow easy identification of human medicines that are subject to additional monitoring and to encourage adverse-reaction reporting for all medicines”.

The EMA's pharmacovigilance plans came into force in July 2012, and include the formation of the Pharmacovigilance Risk Assessment Committee (PRAC) to oversee drug safety issues in the EU.

Other plans include the introduction of an automatic urgent procedure for review at EU level and greater transparency for pharma companies that withdraw a medicine from the market.

19th March 2013

From: Regulatory, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Patient-centred care innovation in dementia: a conversation with Neil Maiden
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators...
Issue 4: SPOTLIGHT ON… Medical Communications in 2017
Make 2017 the year to be heard!...
Market access in Europe: balancing access and affordability
European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs...

Infographics